These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 20210754)

  • 1. Cyclin-dependent kinase inhibitors as anticancer drugs.
    Krystof V; Uldrijan S
    Curr Drug Targets; 2010 Mar; 11(3):291-302. PubMed ID: 20210754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy.
    Grant S; Roberts JD
    Drug Resist Updat; 2003 Feb; 6(1):15-26. PubMed ID: 12654284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
    Senderowicz AM
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel small molecule cyclin-dependent kinases modulators in human clinical trials.
    Senderowicz AM
    Cancer Biol Ther; 2003; 2(4 Suppl 1):S84-95. PubMed ID: 14508085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDK inhibitors in cancer therapy: what is next?
    Malumbres M; Pevarello P; Barbacid M; Bischoff JR
    Trends Pharmacol Sci; 2008 Jan; 29(1):16-21. PubMed ID: 18054800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin-dependent kinase inhibitors.
    Dai Y; Grant S
    Curr Opin Pharmacol; 2003 Aug; 3(4):362-70. PubMed ID: 12901944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDK7 inhibitors as anticancer drugs.
    Sava GP; Fan H; Coombes RC; Buluwela L; Ali S
    Cancer Metastasis Rev; 2020 Sep; 39(3):805-823. PubMed ID: 32385714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy.
    Senderowicz AM
    Cancer Chemother Biol Response Modif; 2001; 19():165-88. PubMed ID: 11686013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein.
    Wesierska-Gadek J; Schmid G
    Expert Opin Investig Drugs; 2006 Jan; 15(1):23-38. PubMed ID: 16370931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDK inhibitors in clinical development for the treatment of cancer.
    Fischer PM; Gianella-Borradori A
    Expert Opin Investig Drugs; 2003 Jun; 12(6):955-70. PubMed ID: 12783600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-molecule cyclin-dependent kinase modulators.
    Senderowicz AM
    Oncogene; 2003 Sep; 22(42):6609-20. PubMed ID: 14528286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).
    Di Giovanni C; Novellino E; Chilin A; Lavecchia A; Marzaro G
    Expert Opin Investig Drugs; 2016 Oct; 25(10):1215-30. PubMed ID: 27606939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDK inhibitors: from the bench to clinical trials.
    Rizzolio F; Tuccinardi T; Caligiuri I; Lucchetti C; Giordano A
    Curr Drug Targets; 2010 Mar; 11(3):279-90. PubMed ID: 20210753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin-dependent kinases as targets for cancer therapy.
    Senderowicz AM
    Cancer Chemother Biol Response Modif; 2002; 20():169-96. PubMed ID: 12703205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases.
    Hirai H; Kawanishi N; Iwasawa Y
    Curr Top Med Chem; 2005; 5(2):167-79. PubMed ID: 15853645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents.
    Dai Y; Grant S
    Curr Oncol Rep; 2004 Mar; 6(2):123-30. PubMed ID: 14751090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin-dependent kinase modulators studied at the NCI: pre-clinical and clinical studies.
    Sausville EA
    Curr Med Chem Anticancer Agents; 2003 Jan; 3(1):47-56. PubMed ID: 12678914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).
    Malínková V; Vylíčil J; Kryštof V
    Expert Opin Ther Pat; 2015; 25(9):953-70. PubMed ID: 26161698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin-dependent kinases as new targets for the prevention and treatment of cancer.
    Senderowicz AM
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1229-53. PubMed ID: 12512390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.